Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

ViiV Healthcare · NCT07525544

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
214
US sites recruiting
1
Study start
May 14, 2026
Record last updated
July 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

VH4770359 (also known as GSK4770359) is an antiretroviral compound. This first-in-human study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered VH4770359 in healthy participants. The findings from this study will support the design of future clinical studies of VH4770359 in people living with HIV.

Being studied: VH4770359; Placebo; Midazolam

Conditions: HIV Infections

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • 18 to 55 years old
  • BMI 18.5-37.0 kg/m2
  • Male participants must adhere to contraception requirements or abstinence, and female participants must not be pregnant/breastfeeding and be of non-childbearing potential.

Exclusion Criteria

  • Participants with significant medical history that could alter drug pharmacokinetics, pose a risk, or interfere with conduct.
  • Has exclusionary psychiatric, hepatic, cardiovascular, gastrointestinal, respiratory, endocrine, neurological, hematological, or renal condition, or exclusionary malignancy.
  • A positive test(s) for Hepatitis B surface antigen (HBsAg) and/or anti-HBc, hepatitis C antibodies, or human immunodeficiency virus (HIV).
  • A history of or ongoing high-risk behaviors for HIV acquisition.
  • Use of prohibited medications.
  • Exclusionary allergies or sensitivities.
  • Regular use of alcohol, drugs of abuse, tobacco, or nicotine products.
  • Exclusionary prior or concurrent clinical study participation.

Recruiting US locations

  • GSK Investigational Site

    Baltimore, MD 21225

    Site contact: US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com

Study contacts (from the official record)

  • US GSK Clinical Trials Call Center · 877-379-3718 · GSKClinicalSupportHD@gsk.com
  • EU GSK Clinical Trials Call Center · +44 (0) 20 89904466 · GSKClinicalSupportHD@gsk.com
All healthy volunteers studies in Maryland →
A Study to Investigate the Safety and PK of VH4770359 in Healthy… (NCT07525544) | Bored Studies